šŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Windward Bio Group AG (WWB)
null: WWB Ā· Real-Time Price Ā· USD
24.01
+1.37 (6.05%)
Nov 19, 2026, 4:00 PM EST - Market closed

Company Description

Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases.

Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease.

The company has collaboration agreements with Sichuan Kelun-Biotech BioPharmaceutical Co., Ltd, Harbour BioMed (Shanghai) Co., Ltd, and Qyuns Therapeutics Co., Ltd. Windward Bio Group AG was incorporated in 2024 and is based in Basel, Switzerland.

Windward Bio Group AG
CountrySwitzerland
Founded2024
IPO DateNov 13, 2026
IndustryBiotechnology
SectorHealthcare
Employees38
CEOLuca Santarelli

Contact Details

Address:
Aeschenplatz 6
Basel, 4052
Switzerland
Phone41 61 551 75 75
Websitewindwardbio.com

Stock Details

Ticker SymbolWWB
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$17.00
CIK Code2145089
ISIN NumberCH1623933509
SIC Code2836

Key Executives

NamePosition
Luca SantarelliChief Executive Officer and Chair of the Board of Directors
Claudia D’AugustaChief Financial Officer
Omar KhwajaChief Medical Officer
Kevin HarrisChief Operating Officer
Scott ApplebaumChief Legal and Corporate Development Officer
David P. BonitaDirector
Timothy AndersonDirector
Naveed I. SiddiqiDirector
Iqbal MuftiDirector
Otello StampacchiaDirector

Latest SEC Filings

DateTypeTitle
Nov 16, 20266-KReport of foreign issuer
Nov 16, 2026424B4Prospectus
Nov 16, 2026S-8Securities to be offered to employees in employee benefit plans
Nov 13, 2026S-8Securities to be offered to employees in employee benefit plans
Nov 13, 2026FWPFree Writing Prospectus
Nov 12, 2026EFFECTNotice of Effectiveness
Nov 12, 2026CERTCertification by an exchange approving securities for listing
Nov 9, 20268-A12BRegistration of securities
Nov 9, 2026F-1/A[Amend] Registration statement for certain foreign private issuers
Oct 30, 2026F-1/A[Amend] Registration statement for certain foreign private issuers
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides